JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Irie, M.
Right arrow Articles by Inui, K.-I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Irie, M.
Right arrow Articles by Inui, K.-I.

Vol. 298, Issue 2, 711-717, August 2001

Recognition and Transport Characteristics of Nonpeptidic Compounds by Basolateral Peptide Transporter in Caco-2 Cells

Megumi Irie, Tomohiro Terada, Kyoko Sawada, Hideyuki Saito and Ken-Ichi Inui

Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan

Recent studies have revealed that diverse compounds lacking peptide bonds, such as valacyclovir and delta -aminolevulinic acid (delta -ALA), can be recognized by H+-coupled peptide transporters (PEPT1 and PEPT2). In the present study, recognition and transport characteristics of nonpeptidic compounds by the basolateral peptide transporter, which is distinct from PEPTs, were compared with those by PEPT1 using the human intestinal Caco-2 cells. [14C]Glycylsarcosine uptake via PEPT1 was inhibited by all nonpeptidic compounds tested. Similarly, most nonpeptidic compounds showed an inhibitory effect on [14C]glycylsarcosine uptake by the basolateral peptide transporter, although some kinds of nonpeptidic compounds, such as valine methyl ester, did not. Direct measurements of valacyclovir and delta -ALA transport revealed that both compounds were able to be transported by the basolateral peptide transporter. Because delta -ALA has been used recently in vitro and in clinical studies as an endogenous photosensitizer for photodynamic therapy, the intestinal transport characteristics of delta -ALA were further examined. Inhibition studies and Eadie-Hofstee plot analysis suggested that delta -ALA transport across the brush-border and basolateral membranes of the intestine was mainly mediated by peptide transporters. In addition, the apical-to-basolateral transport of delta -ALA was greater than that of the opposite direction. These findings provide the first evidence that the intestinal basolateral peptide transporter can recognize and transport nonpeptidic compounds, and play a definitive role in the absorption of delta -ALA.

0022-3565/01/2982-0711$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. V. S. Varma, A. H. Eriksson, G. Sawada, Y. A. Pak, E. J. Perkins, and C. L. Zimmerman
Transepithelial Transport of the Group II Metabotropic Glutamate 2/3 Receptor Agonist (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and Its Prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344)
Drug Metab. Dispos., January 1, 2009; 37(1): 211 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Bourre, F. Giuntini, I. M. Eggleston, M. Wilson, and A. J. MacRobert
5-Aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy
Mol. Cancer Ther., June 1, 2008; 7(6): 1720 - 1729.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Tsuda, T. Terada, M. Irie, T. Katsura, A. Niida, K. Tomita, N. Fujii, and K.-i. Inui
Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypotensive Drug Midodrine, and Its Amino Acid Derivatives
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 455 - 460.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. K. Bhardwaj, D. Herrera-Ruiz, P. J. Sinko, O. S. Gudmundsson, and G. Knipp
Delineation of Human Peptide Transporter 1 (hPepT1)-Mediated Uptake and Transport of Substrates with Varying Transporter Affinities Utilizing Stably Transfected hPepT1/Madin-Darby Canine Kidney Clones and Caco-2 Cells
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1093 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
M. Irie, T. Terada, T. Katsura, S. Matsuoka, and K.-i. Inui
Computational modelling of H+-coupled peptide transport via human PEPT1
J. Physiol., June 1, 2005; 565(2): 429 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
D. A. Groneberg, A. Fischer, K. F. Chung, and H. Daniel
Molecular Mechanisms of Pulmonary Peptidomimetic Drug and Peptide Transport
Am. J. Respir. Cell Mol. Biol., March 1, 2004; 30(3): 251 - 260.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Neumann and M. Brandsch
delta -Aminolevulinic Acid Transport in Cancer Cells of the Human Extrahepatic Biliary Duct
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 219 - 224.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Zhao, G. Luo, G.-M. Zhao, P. W. Schiller, and H. H. Szeto
Transcellular Transport of a Highly Polar 3+ Net Charge Opioid Tetrapeptide
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 425 - 432.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.